JP2023522065A - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP2023522065A
JP2023522065A JP2022563012A JP2022563012A JP2023522065A JP 2023522065 A JP2023522065 A JP 2023522065A JP 2022563012 A JP2022563012 A JP 2022563012A JP 2022563012 A JP2022563012 A JP 2022563012A JP 2023522065 A JP2023522065 A JP 2023522065A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
total weight
amount
api
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522065A5 (https=
Inventor
ワン，ゼレン
シュ，ジュン
ファリーナ，ピーター
チェン，シュン
Original Assignee
シェンチェン・ファーマシン・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シェンチェン・ファーマシン・カンパニー・リミテッド filed Critical シェンチェン・ファーマシン・カンパニー・リミテッド
Publication of JP2023522065A publication Critical patent/JP2023522065A/ja
Publication of JP2023522065A5 publication Critical patent/JP2023522065A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022563012A 2020-04-17 2021-04-16 医薬組成物 Pending JP2023522065A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/085241 2020-04-17
CN2020085241 2020-04-17
PCT/CN2021/087690 WO2021209025A1 (en) 2020-04-17 2021-04-16 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2023522065A true JP2023522065A (ja) 2023-05-26
JP2023522065A5 JP2023522065A5 (https=) 2024-04-26

Family

ID=78084668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563012A Pending JP2023522065A (ja) 2020-04-17 2021-04-16 医薬組成物

Country Status (8)

Country Link
US (1) US20230128252A1 (https=)
EP (1) EP4135699A4 (https=)
JP (1) JP2023522065A (https=)
KR (1) KR20230004644A (https=)
CN (1) CN115135323A (https=)
AU (1) AU2021255559A1 (https=)
CA (1) CA3180160A1 (https=)
WO (1) WO2021209025A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240390366A1 (en) * 2021-11-30 2024-11-28 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
CN116115563B (zh) * 2023-03-30 2023-08-29 石家庄四药有限公司 一种氟比洛芬混悬注射液及其制备方法
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions
CN117731649B (zh) * 2023-12-21 2025-01-28 博济医药科技股份有限公司 一种氨甲环酸药物组合物及其制备工艺
CN119837856A (zh) * 2024-12-11 2025-04-18 江南大学 一种具有预防和改善特应性皮炎的黄酮组合物及其应用
CN120865107B (zh) * 2025-09-22 2026-01-23 中国医学科学院医药生物技术研究所 一种苯吩嗪衍生物、其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814814C2 (de) * 1998-04-02 2002-01-31 Gerhard Steffan Wasserlösliche, Iminophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US10179159B2 (en) * 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
CN102225046A (zh) * 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
CA2775393C (en) * 2012-05-02 2014-04-29 Samy Saad Topical non-aqueous pharmaceutical formulations
US8852648B2 (en) * 2012-11-06 2014-10-07 Rochal Industries, Llp Delivery of biologically-active agents using volatile, hydrophobic solvents
CN105492004A (zh) * 2013-02-08 2016-04-13 罗达制药有限公司 治疗局部微生物感染的方法
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
CN105693668A (zh) * 2016-04-23 2016-06-22 贺玉皓 一种氯法齐明的药物组合物及其医药用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B.P.B ELLIS, AND E.TAUBE, S. AFR. MEDICAL JOURNAL, vol. 47, JPN6025016951, 1973, pages 378 - 379, ISSN: 0005581843 *
CORNEL BURGER ET AL., PHARM RES, vol. 35, JPN6025016952, 2018, pages 186, ISSN: 0005581844 *
M.C.PRABHAKAR ET AL., ADVANCES IN PHARMACOLOGY AND TOXICOLOGY, vol. 13, no. 2, JPN6025016949, 2012, pages 65 - 70, ISSN: 0005710239 *

Also Published As

Publication number Publication date
WO2021209025A1 (en) 2021-10-21
AU2021255559A1 (en) 2022-11-17
US20230128252A1 (en) 2023-04-27
EP4135699A4 (en) 2024-05-01
EP4135699A1 (en) 2023-02-22
KR20230004644A (ko) 2023-01-06
CA3180160A1 (en) 2021-10-21
CN115135323A (zh) 2022-09-30

Similar Documents

Publication Publication Date Title
JP2023522065A (ja) 医薬組成物
US10758502B2 (en) High concentration local anesthetic formulations
KR102235922B1 (ko) 테트라사이클린 국소 제제, 제조방법, 및 이의 용도
EP2877155B1 (en) Opioid formulations
US20190216779A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
JP2018193377A (ja) ステロイドの抗痙攣活性
JP7602324B2 (ja) 重水素化ドンペリドン組成物、方法、及び調製
EP3104844B1 (en) Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
KR20110013348A (ko) 통증 치료를 위한 라놀라진의 용도
US20240245713A1 (en) Long-acting injectable formulations and use thereof
US9572825B2 (en) Compositions and methods for treating huntington's disease
AU2019200982A1 (en) Opioid formulations
KR20200051854A (ko) 코르티코스테로이드를 포함하는 국소용 조성물
KR20120118495A (ko) 국부 마취제 에멀전 조성물 및 이의 제조 및 사용 방법
CN115916142A (zh) 偶联萜烯缀合物
TWI729371B (zh) 治療搔癢症的組合物與方法
CN110402142A (zh) 含局麻药的酸性乳液组合物
US20050158371A1 (en) Novel external agent
WO2023108074A1 (en) Novel salvinorin compositions
WO2016052617A1 (ja) ナルフラフィン含有局所適用製剤
CN115279788A (zh) 用于治疗银屑病和其他疾病的外用环孢霉素
HK1205948B (en) Opioid formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251017